Q-omics provides the consensus-scored LINC01615 profile across patient tissues and cancer cell-line models. LINC01615 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01615 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LINC01615 RNA expression shows 14,377 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where LINC01615 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01615 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01615 survival associations across molecular data types. LINC01615 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01615 RNA expression–survival associations across cancer types. High LINC01615 expression shows unfavorable associations in KIRP, MESO, UVM, BRCA and KIRC, but favorable associations in DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01615 RNA expression.
This table summarizes LINC01615 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01615. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01615 shows higher tumor expression in HNSC, BLCA, KIRC, COAD, LUAD and STAD. The HNSC box plot shows higher LINC01615 RNA expression in tumor versus normal tissue (log2 FC = +2.943, t-test p < 0.001).
This table shows molecular features associated with LINC01615 in patient tissues and cancer cell lines. In patient samples, LINC01615 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
